Invesco's RSPH vs. PJP: Which Health Care ETF Is the Better Fund For The GLP-1 Revolution?
Compare portfolio strategies, cost structures, and risk profiles as two Invesco healthcare ETFs take different paths to sector exposure.
Invesco's RSPH vs. PJP: Which Health Care ETF Is the Better Fund For The GLP-1 Revolution?
Overview
Weight loss drug advances, including GLP-1s, have revolutionized health care. For investors looking to capitalize on the GLP-1 trend, two funds are worth considering. The Invesco S&P 500 Equal Weight Health Care ETF (NYSEMKT:RSPH) offers a broader, lower-cost approach to healthcare, while the Invesco Pharmaceuticals ETF (NYSEMKT:PJP) provides a concentrated, factor-based strategy focused specifically on pharmaceutical firms.
Both funds target the healthcare sector but use fundamentally different methodologies to select and weight securities. While RSPH focuses on broad sector exposure through an equal-weighting lens, PJP homes in on the pharmaceutical sub-sector using a proprietary index that prioritizes factor-based performance metrics like momentum and earnings growth.
Details
Beta measures price volatility relative to the S&P 500; beta is calculated from five-year monthly returns. The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield as of the closing price of each fund on June 12, 2026. AUM refers to total assets under management.
Source
Originally published at www.fool.com.
